Review Article

Effectiveness of Combination of Leflunomide and Methotrexate Compared to Etanercept in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Abstract

Context: Rheumatoid arthritis (RA) is a chronic progressive systemic inflammatory condition, which affects mainly the joint synovial and does not have a definitive treatment. Data was collected using the American College of Rheumatology (ACR) score, and different levels of improvement were shown as ACR20, ACR50, and ACR70. The aim of this study was to compare the effectiveness of combination of leflunomide and methotrexate (LEF + MTX) to etanercept (ETN).
Methods: This systematic review was performed to evaluate the effectiveness of LEF + MTX in comparison with ETN. Electronic databases, including cochrane, PubMed, Scopus, and CRD, were searched up to December 2015. Quality assessment was conducted by the Jadad scale and the Cochrane Collaboration’s tools. Meta-analysis was conducted for effective outcomes of the included studies. Effectiveness was measured by ACR. This review was updated up to January 2019.
Results: Overall, 2780 eligible articles were retrieved, five of which were eligible for inclusion. Effectiveness outcomes showed an improvement in ACR criteria. Differences in the improvement of ACR70, ACR50, and ACR20 criteria in LEF + MTX groups compared to placebo groups were reported 0.78%, 20%, and 27%, respectively, and these differences compared to ETN groups were respectively 0.003%, 21.93%, and 32%.
Conclusions: Combination of leflunomide and methotrexate is effective, and it can be used as before biomedical medications such as etanercept, as it is more cost-effective.

1. Goekoop YP, Allaart, C. R., Breedveld, F. C., & Dijkmans, B. A. (2001). Combination therapy in rheumatoid arthritis. Current opinion in rheumatology, 13(3), 177-183.‏.
2. Lee DM WMRaL.
3. Linos A, Worthington, J. W., O'FALLON, M. I. C. H. A. E. L., & Kurland, L. T. (1980). The epidemiology of rheumatoid arthritis in Rochester Minnesota: a study of incidence, prevalence, and mortality. American Journal of Epidemiology, 111(1), 87-98.‏.
4. Lawrence JSSorcitpPiCR, J&A Churchill, London, 1.
5. Pincus T, & Callahan, L. F. (1986). Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity. The Journal of rheumatology, 13(5), 841.‏.
6. Arnett FC, Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., ... & Medsger, T. A. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism, 31(3), 315-324.‏ ISO 690.
7. Inoue K, Shichikawa, K., Nishioka, J., & Hirota, S. (1987). Older age onset rheumatoid arthritis with or without osteoarthritis. Annals of the rheumatic diseases, 46(12), 908-911.
8. Valesini G, Di Franco, M., Spinelli, F. R., & Scrivo, R. (2008). Induction of remission in rheumatoid arthritis: criteria and opportunities. Rheumatology international, 29(2), 131-139.‏.
9. Aletaha D, & Smolen, J. S. (2007). The simplified disease activity index (SDAI) and clinical disease activity index (CDAI) to monitor patients in standard clinical care. Best practice & research Clinical rheumatology, 21(4), 663-675.‏.
10. Utsinger PD, Zvaifler, N. J., & Ehrlich, G. E. (1985). Rheumatoid arthritis: etiology, diagnosis, management. Lippincott Williams & Wilkins.‏.
11. Schur PH CSTorartiDtiaIU, Basow, DS (Ed), UpToDate, Waltham, MA. Cited 3/24/14.
12. Blumenauer BBTB, Judd, M., Cranney, A., Burls, A., Coyle, D., Hochberg, M., ... & Wells, G. (2003). Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev, 4.‏.
13. Moreland LW SM, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. Mar 16 1999;130(6):478-486.
14. Hobbs K DA, Wang B, et al. Rheumatoid Arthritisndomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Etanercept in patients with moderheumatoid arthritistely active Rheumatoid Arthritis despite DMARD therheumatoid arthritispy. Springerplus 2015;4:113.
15. Keystone EC SM, Kremer JM, Kafka S, Lovy M, De Vries T, et al. Once-Weekly Administrheumatoid arthritistion of 50 mg Etanercept in Patients with Active Rheumatoid Arthritis: Results of a Multicenter, Rheumatoid Arthritisndomized, Double-Blind, Placebo-Controlled Trial. Arthritis and Rheumatism 2004;50:353-63.
16. Kremer J M GM, Cannon GW, Caldwell JR, Cush J J, Furst D E, Kaine JL.Concomitant leflunomide therheumatoid arthritispy in patients with active Rheumatoid Arthritis despite stable doses of methotrexate: a Rheumatoid Arthritisndomized, double-blind, placebo-controlled trial. Annals of internal medicine 2002; 137: 726-733.
17. Moreland LW BS, Schiff MH, et al. Treatment of Rheumatoid Arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med Jul 17 1997;337:141-147.
18. Weinblatt ME BJ, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). Mar 2011;63(3):373-382.
19. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 2006;65(12):1578-84.
20. Dore RK MS, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. Jan-Feb 2007;25(1):40-46.
21. Ropes MW, Bennett, G. A., COBB, S., JACOX, R., & Jessar, R. A. (1958). 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bulletin on the rheumatic diseases, 9(4), 175-176.
22. Londono J SA, Santos PI, Cubidez MF, Guzman C, Valle-Oñate R. Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. Revista Brasileira de Reumatologia. 2012;52(6):837-845.
Files
IssueVol 4, No 4 (2020) QRcode
SectionReview Article
DOI https://doi.org/10.18502/htaa.v4i4.6872
Keywords
Rheumatoid Arthritis Leflunomide Methotrexate Etanercept
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Iman R, Khaledi L. Effectiveness of Combination of Leflunomide and Methotrexate Compared to Etanercept in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Health Tech Ass Act. 2021;4(4).